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Introduction
Both acute thrombotic and chronic critical lower 
limb ischaemia are associated with high morbidity 
and mortality, and also with a  high risk of unsuc-
cessful revascularisation of the limb, requiring its 
amputation. Routine management of both types of 
limb ischaemia consists of anticoagulation followed 
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A b s t r a c t
Introduction: Mechanical thrombectomy is an alternative to local thrombolysis for the treatment of severe ischaemia 
in the femoropopliteal segment, but stent implantation is usually required after this procedure. The use of drug-elut-
ing balloons (DEBs) may overcome long-term problems associated with stents, but it remains unclear how often such 
a treatment is technically feasible and efficient.
Aim: This post hoc single-centre study was aimed at assessment of the feasibility, safety and efficacy of mechanical 
thrombectomy followed by application of DEBs.
Material and methods: Fifty-one patients, aged 69.1 ±11.6 years, were managed for acute thrombotic or chronic 
critical ischaemia in the femoropopliteal segment using the Rotarex device. Following mechanical thrombectomy, on 
condition that there was no significant residual stenosis or dissection, lesions were managed with paclitaxel-coated 
DEBs, which was a desired strategy (24 patients). The remaining 25 patients underwent stent implantations, which 
was regarded as bailout treatment. Final follow-up was scheduled 12 months after the procedure.
Results: The primary-assisted patency rate after mechanical rotational thrombectomy with additional balloon angio-
plasty and/or stenting was 97.1% (49 patients). The early mortality rate was 2.0% (1 patient) and the amputation 
rate was 4.1% (2 patients). There were no late mortalities or limb amputations at 12-month follow-up, but significant 
restenoses occurred in 13 (27.1%) patients. These restenoses were more frequent in patients who underwent stent 
implantation (45.5%) than those managed with DEBs (12.5%), and in patients managed for secondary lesions.
Conclusions: In selected patients mechanical rotational thrombectomy in the femoropopliteal segment followed by 
application of DEB is a safe, effective and long-lasting method of revascularisation.
Key words: critical ischaemia, stent, drug-eluting balloon, mechanical thrombectomy, acute limb ischaemia.
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by open surgical repair of occluded arteries (usually 
bypass grafting) [1–4]. Yet, such a treatment in pa-
tients with acute thrombotic ischaemia is associated 
with an amputation rate at the level of 10–70% and 
in-hospital mortality even as high as 15% [5]. In pa-
tients with critical limb ischaemia the amputation 
rate after surgical revascularization is at the level of 
20–25% and the 2-year mortality rate in these pa-
tients is about 50% [2, 5, 6]. Although local throm-
bolysis is associated with better clinical outcomes 
and currently it is preferred to surgical revascular-
ization [7–10], not all occlusions can be opened by 
thrombolytic agents. Those primarily atherosclerot-
ic poorly respond to thrombolysis. Moreover, even 
if thrombolysis is successful, these arteries usually 
re-occlude and stent implantation is often required, 
which carries another problem ‒ in-stent stenosis or 
occlusion, primarily associated with intimal hyper-
plasia within the stent. Mechanical thrombectomy 
seems to be an alternative treatment modality [5, 
11–14], but stent implantation with similar late 
problems is usually required after this endovascular 
procedure. The use of drug-eluting balloons (DEB) 
instead of stents may theoretically overcome clini-
cal problems associated with stents, but it remains 
unclear how often such a  treatment is technically 
feasible in these challenging patients and how ef-
ficient mechanical thrombectomy not augmented 
with stent implantations is in the long run. 
Aim
This post hoc single-centre study was aimed at 
assessment of the feasibility, safety and efficacy 
of mechanical thrombectomy followed by applica-
tion of DEBs for acute thrombotic or chronic critical 
ischaemia of the lower limbs in the femoropoplite-
al segment. We also analysed how often the use of 
rotational thrombectomy enabled an endovascular 
procedure not accompanied by stent implantation, 
and whether the utilisation of DEBs instead of stents 
was associated with a better clinical outcome.
Material and methods
We reviewed our register of endovascular in-
terventions and identified patients with acute 
thrombotic ischaemia or chronic critical lower limb 
ischaemia due to occlusions in the femoropoplite-
al segment, who were managed using mechanical 
rotational thrombectomy (Rotarex®s device; Straub 
Medical AG, Wangs, Switzerland). Technical success 
of mechanical rotational thrombectomy was defined 
in terms of absence of relevant post-procedural re-
sidual stenosis, with cutoff at the level of 50%. Pri-
mary-assisted patency rate was defined as exempt 
from significant stenosis (cutoff at the level of 30%) 
in the target artery following rotational thrombec-
tomy and additional endovascular interventions 
during the primary procedure, such as balloon an-
gioplasty and stenting.  
Potential risks and benefits associated with such 
a procedure were discussed with the patients, and 
all patients gave their written informed consent. 
Clinical indications for mechanical rotational throm-
bectomy in our centre included:
–  occlusions and/or critical stenoses of the distal 
femoral artery (distally from the profunda femoris 
artery) or the popliteal artery (with or without in-
volvement of its branches);
–  atherosclerotic, atherothrombotic and atheroaneu-
rysmatic lesions;
–  primary lesions and secondary lesions after pre-
vious balloon angioplasty or stent implantations.
Exclusion criteria comprised: highly calcified 
lesions,  no adequate vascular access, contraindi-
cations for antiplatelet therapy, and lack of the pa-
tient’s consent. 
In this study we did not include patients present-
ing with arterial emboli. From June 2014 to Novem-
ber 2016 there were 51 eligible patients, 26 men and 
25 women, with a  mean age of 69.1 ±11.6 years. 
Thirteen (25.5%) patients were managed for acute 
non-embolic occlusions of the distal femoral artery 
and/or popliteal artery and its branches. Out of 
these patients, 6 (46.2%) presented with an acutely 
occluded stent. Thirty-eight (74.5%) patients were 
admitted to the hospital because of critical limb 
ischaemia resulting from atherothrombotic lesions 
at the same level as patients with acute ischaemia. 
In this group there were 5 (13.2%) patients with 
thrombotic occlusions after balloon angioplasty and 
18 (47.4%) patients with chronically occluded stents. 
A majority of patients presented with grade 4 and 5 
(21 and 25 patients, accordingly) of the Rutherford 
classification, and 5 patients presented with severe 
ischaemic ulcers (grade 6 in this classification). The 
demographic profile of both groups of patients and 
their co-morbidities are presented in Table I, while 
localisations and characteristics of arterial lesions 
are described in Table II. 
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Endovascular procedures were performed 
through ipsi- or contralateral femoral access. Before 
intervention all patients received 300 mg of clopido-
grel and 75 mg of aspirin. During endovascular in-
tervention patients were administered intravenously 
unfractionated heparin. Dosing of heparin depended 
on the duration of the procedure. We used 110 cm or 
135 cm long 6 Fr Rotarex®s catheters. Firstly we nav-
igated through the occluded segment with a 0.018” 
guidewire and then performed 2–6 passages of the 
Rotarex system. After at least 2 passages of the 
rotational catheter, control catheter angiography 
was performed. If there was still over 50% steno-
sis, balloon angioplasty was performed. Afterwards, 
if there was no major residual stenosis (over 40%) 
in the target artery and no significant dissection, 
this area was managed with paclitaxel-coated DEBs, 
such as Elutax SV (Aachen Resonance, Aachen, 
Table I. Clinical characteristics of patients
Parameter All patients
(n = 51)
Critical limb ischaemia  
(n = 38)
Acute non-embolic limb 
ischaemia (n = 13)
Male/female ratio 26/25 (51.0/49.0%) 17/21 (44.7/55.3%) 9/4 (69.2/30.8%)
Patients’ age [years] 69.1 ±11.6 70.2 ±11.8 67.9 ±15.5
Diabetes mellitus type 2 20 (39.2%) 12 (31.6%) 8 (61.5%)
Cigarette smoking 17 (33.3%) 13 (34.2%) 6 (46.2%)
Hypercholesterolaemia 22 (43.1%) 16 (42.1%) 6 (46.2%)
Arterial hypertension 44 (86.3%) 34 (89.5%) 10 (76.9%)
Family history cardiovascular disease 9 (17.6%) 7 (18.4%) 2 (15.4%)
History of myocardial infarction 11 (21.6%) 7 (18.4%) 4 (30.8%)
Table II. Localisations and characteristics of arterial lesions
Variable All patients
(n = 51)
Critical limb ischaemia 
(n = 38)
Acute non-embolic limb 
ischaemia (n = 13)
Distal part of femoral artery 12 (23.5%) 10 (26.3%) 2 (15.4%)
Popliteal artery 14 (27.5%) 10 (26.3%) 4 (30.8%)
Distal part of femoral artery and 
popliteal artery
16 (31.4%) 13 (34.2%) 7 (53.8%)
Popliteal artery and its branches 7 (13.7%) 5 (13.2%) 2 (15.4%)
Popliteal artery with aneurysmatic 
dilatation
3 (5.9%) 1 (2.6%) 2 (15.4%)
Distal part of femoral artery and 
popliteal artery with aneurysmatic 
dilatation
2 (3.9%) 2 (5.3%) 0
Mean length of the lesion [mm] 247.0 ±135.8 253.2 ±129.9 303.8 ±140.0
Thrombosis in the area of lesion 34 (66.7%) 22 (57.9%) 12 (92.3%)
Total occlusion of the target artery 44 (86.3%) 31 (81.6%) 13 (100%)
Degree of stenosis (%) 93 ±3.1 92 ±2.2 100
Ankle/brachial index at baseline 0.2 ±0.1 0.4 ±0.15 0.2 ±0.15
Primary lesion 26 (51.0%) 19 (50.0%) 7 (53.8%)
Restenotic lesion 25 (49.0%) 19 (50.0%) 6 (46.2%)
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Germany) or Luminor (iVascular, Barcelona, Spain). 
This was a desired strategy, which was possible in 
24 patients (49.0%). In 25 (51.0%) patients arteries 
revealed significant stenoses despite balloon an-
gioplasty, or there were severe (grade C or higher) 
dissections. These patients underwent stent implan-
tations, which was regarded as a bailout treatment. 
In addition, 6 (11.8%) patients presenting with over 
60% residual stenosis following balloon angioplasty 
and/or significant peripheral embolisation received 
alteplase intra-arterially (5 mg as a bolus, and then 
15 mg during 12 h). Details regarding results of ro-
tational mechanical thrombectomy with the Rotarex 
system are given in Tables III and IV.
All patients were assessed before discharge from 
the hospital. They were discharged with the recom-
mendation of dual antiplatelet therapy with aspirin 
(75–150 mg daily) and clopidogrel (75 mg daily). 
Their follow-ups were scheduled 30 days, 6 and 
12 months after the procedure. Since there was 1 death 
and 2 amputations during the hospital stay, only 
48 patients were followed up (24 patients managed 




Critical limb ischaemia 
(n = 38)
Acute non-embolic limb 
ischaemia (n = 13)
Number of passages of the Rotarex 
system 
3 ±2 4 ±2 3 ±1
Degree of stenosis after mechanical 
thrombectomy (%)
54 ±15 55 ±15 45 ±13
Duration of mechanical  
thrombectomy [min]
5 ±2 7 ±2 5 ±2
Patients finally managed with 
drug-eluting balloons
24 19 5
Degree of residual stenosis after  
drug-eluting balloons (%)
13.5 ±4 10.5 ±6 12.5 ±9
Patients finally managed with stents 27 19 8
Degree of residual stenosis after  
stenting (%)
11.5 ±4 10.5 ±6 10.5 ±6
Ankle/brachial index at hospital 
discharge
0.73 ±0.10 0.75 ±0.12 0.75 ±0.14
Table IV. Results of rotational mechanical thrombectomy with Rotarex system in patients finally managed 
with drug-eluting balloons vs. those managed with stents.
Variable All patients
(n = 51)
Patients managed with drug-
eluting balloons (n = 24)
Patients managed with 
stents (n = 27)
Patients presenting with critical limb 
ischaemia 
38 (74.5%) 19 (79.2%) 19 (70.4%)
Patients presenting with acute 
non-embolic limb ischaemia
13 (25.5%) 5 (20.8%) 8 (29.6%)
Number of passages of the Rotarex 
system
4 ±2 3 ±1 4 ±1
Degree of stenosis after mechanical 
thrombectomy (%)
47 ±20 41 ±18 45 ±13
Degree of residual stenosis after  
balloon angioplasty and/or  stenting (%)
14.3 ±6 21.5 ±12 10.5 ±6
Ankle/brachial index at hospital 
discharge
0.71 ±0.14 0.72 ±14 0.70 ±0.12
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with DEBs and 22 patients who underwent stent im-
plantation). At each visit patients underwent physi-
cal examination, evaluation of degree of limb isch-
aemia according to the Rutherford classification and 
duplex sonography of the recanalised arteries. Pa-
tients were also evaluated in a case of clinical wors-
ening or delayed wound healing. Clinical worsening, 
restenosis revealed by sonographic examination and 
delayed healing of an arterial ulcer were the indica-
tions for control angiography and reintervention. 
Statistical analysis
Multivariate stepwise backward conditional lo-
gistic regression analysis was used to determine 
independent predictors of restenosis/occlusion. The 
significance of this analysis was set at p < 0.05. 
Results
Technical success of mechanical rotational 
thrombectomy alone was achieved in 20 (19.6%) 
patientsand there was a 97.1% primary-assisted pa-
tency rate (49 patients) after additional balloon an-
gioplasty and stenting. In 2 (4.1%) patients despite 
recanalisation of the target artery and stenting this 
procedure clinically failed and in both of them am-
putations of ischaemic limbs were performed during 
the hospital stay. Such an unfavourable outcome oc-
curred in 1 patient presenting with acute thrombotic 
limb ischaemia and in 1 with chronic critical isch-
aemia. In both patients, in addition to occlusions of 
the distal femoral artery and popliteal artery, there 
were occlusions of the branches of the popliteal 
artery. There was one in-hospital death (mortality 
rate: 2.0%). This patient died because of intracranial 
bleeding, which probably was associated with infu-
sion of alteplase. There were local complications as-
sociated with mechanical thrombectomy in 5 (9.8%) 
patients – distal embolisation in 4 patients, which 
was successfully managed with aspiration and local 
infusion of alteplase, and perforation of the artery 
in 1 case, which required implantation of a covered 
stent. There were neither mortalities nor major ad-
verse events, such as myocardial infarction, stroke or 
limb amputation in all 48 remaining patients during 
12 months of follow-up. At 12 month follow-up the 
clinical status of the majority of ischaemic limbs had 
improved. Only 1 (2.1%) patient suffered from rest 
pain and 7 (14.6%) patients from severe claudica-
tion. There were no patients presenting with isch-
aemic ulcers. Details are given in Figure 1. In 13 pa- 
tients (27.1%, excluding deceased and amputated 
patients) duplex sonography revealed occlusions or 
severe stenoses in the target arteries. These lesions 
primarily occurred in patients managed for second-
ary lesions (12 limbs). There was only 1 patient with 
restenosis after primary intervention. Also, resteno-
ses and occlusions at follow-up were significantly 
more frequent in patients who underwent stent im-
plantation (10 patients; 45.5%) than in those man-
aged with DEBs (3 patients; 12.5%) – Figure 2. The 
risk of recurrent lesions was higher in patients with 
chronic critical lower limb ischaemia (11 patients; 
30.6%) than those managed for acute thrombotic 
occlusions (2 patients; 16.7%). Details are described 
Figure 1. Degree of ischaemia according to the 
Rutherford classification before intervention 
and at 12-month follow-up
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Figure 2. Kaplan-Meier event-free curves dis-
playing the freedom from restenosis/reocclu-
sion in patients managed with drug-eluting bal-
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in Table V. The logistic regression analysis revealed 
that peripheral embolisation during the procedure 
and more than 4 passages of the Rotarex system 
were significantly associated with a  higher risk of 
restenosis/occlusion (hazard ratio: 5.6 and 5.0; p = 
0.018 and 0.025 respectively).
Discussion
In this post-hoc analysis we have demonstrat-
ed that the majority of severe atherothrombotic le-
sions in the femoropopliteal segment that result in 
acute or chronic critical limb ischaemia, and are not 
highly calcified, can be reopened using mechanical 
rotational thrombectomy. In our patient series the 
primary-assisted patency rate after thrombectomy 
augmented by balloon angioplasty and stenting was 
as high as 97.1%. in the in-hospital amputation rate 
was 4.1%. Such management was also safe. In-hos-
pital mortality was 2.0%, which was significantly 
lower than after an open surgical revascularization. 
Moreover, in 49% of patients it was possible to avoid 
stent implantation and instead to manage the area 
of occlusion with DEB. 
Analysis of the clinical outcome of our patients at 
12-month follow-up demonstrated that mechanical 
rotational thrombectomy with the Rotarex system 
followed by DEB was not inferior to such a throm-
bectomy assisted by stent implantation. Actually, 
the results after DEB were better; there were fewer 
restenoses and no amputations. Yet, stents were im-
planted in patients with more advanced pathology 
and therefore these differences should be interpret-
ed with caution. Similarly, although we identified 
peripheral embolisation during the procedure and 
more than 4 passages of the Rotarex system as risk 
factor of reocclusion, these events were probably 
predictors of more advanced arterial disease, and 
thus the risk of reocclusion in these patients was 
higher. Similarly worse late results in patients who 
required local fibrinolysis in addition to mechanical 
thrombectomy have already been reported by Kro-
nlage [5]. 
Large epidemiological studies have revealed 
a significant risk of major amputation and/or mor-
tality associated with open surgical revascularization 
for acute and critical leg ischaemia [1–3, 15]. Conse-
quently, local fibrinolysis or endovascular thrombec-
tomy is currently suggested to be a preferred treat-
ment modality [16–20]. In the large study by Freitas 
et al., who managed with Rotarex 525 patients pre-
senting with acute and subacute ischaemia, with 
an average length of occluding lesions of 159 mm, 
there was 1.1% mortality and a 2.3% major ampu-
tation rate during 30-day follow-up. Adverse events 
associated with the treatment occurred in 6.9% of 
patients and mortality after 1 year was 8% [19]. Sim-
ilar outcomes were reported by Kronlage et al. They 
managed 202 patients and in this group amputa-
tion-free survival was 94.3% [5]. 
Although mechanical thrombectomy with the 
Rotarex system has been demonstrated to be both 
relatively safe and efficient [5, 7–9, 14, 16–19], it re-
mains to be established how to optimize such treat-
ment. Even if short-term results are encouraging, 
long-term patency rates in the femoropopliteal seg-
ment after  standard balloon angioplasty or stent im-
plantation are relatively low. The 1-year reocclusion 
rate after balloon angioplasty is at the level of 60% 
[21–28]. Stents do not seem to be a proper solution 
either. When implanted in this part of the arterial 
system, especially in the distal part of the popliteal 
artery or in its branches, a significant proportion of 
currently available stents occlude in the long run, ei-
ther because of a fracture, or due to thrombosis and 
intimal hyperplasia [21–29]. Although novel wire-in-
Table V. Number of patients presenting with severe restenoses and occlusions at 12-month follow-up (pa-
tients who died or had their limbs amputated during first hospitalization were excluded)
Parameter All patients Critical limb 
ischaemia (n = 36)
Acute non-embolic limb 
ischaemia (n = 12)
All patients (n = 48) 13 (27.1%) 11 (30.6%) 2 (16.7%)
Patients managed with drug-eluting balloons (n = 24) 3 (12.5%) 3 (15.8%) 0
Patients managed with stents (n = 24) 10 (41.7%) 8 (47.1%) 2 (28.6%)
Patients managed for primary lesions (n = 22) 1 (4.5%) 1 (6.7%) 0
Patients managed for secondary lesions (n = 26) 12 (46.2%) 10 (47.6%) 2 (40.0%)
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terwoven Nitinol or helically shaped stents, exhibit-
ing a swirling flow, try to overcome these problems, 
they are not yet routinely used and their actual long-
term advantage remain to be proven [30–35]. On 
the other hand, long-term patency rates in the fem-
oropopliteal segment after DEBs are higher than af-
ter standard balloon angioplasty [36–47], while the 
problems associated with stents are avoided. 
The results of our study suggest that the use of 
DEB after mechanical thrombectomy for thrombotic 
acute or critical leg ischaemia resulting from arte-
rial occlusion in the femoropopliteal segment could 
be a desired treatment strategy. However, it should 
be emphasized that it was a retrospective analysis 
and the groups of patients were not fully compara-
ble. A  larger prospective study should be designed 
and performed in order to fully compare the clini-
cal value of DEBs with stents in these challenging 
patients. Also, probably some novel area-dedicated 
stents (such as the aforementioned helically shaped 
ones) should be applied in such a trial. 
Conclusions
The short and intermediate term results from this 
nonrandomised study indicate that the combination 
of mechanical thrombectomy with DEB is safe and 
feasible for the treatment of intermediate to long 
superficial femoral artery/popliteal artery lesions in 
selected patients with severe limb ischaemia. The 
DEB group had higher rates of primary patency and 
freedom from restenosis than the group of patients 
with stent implantation.
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